Celldex Therapeutics (NASDAQ: CLDX) presented results from a phase 1 study of CDX-622, a bispecific antibody targeting soluble stem cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE